Press Releases

Date Title
Toggle Summary vTv Therapeutics and Reneo Pharmaceuticals Enter Licensing Agreement for PPAR-Delta Program
HIGH POINT, N.C. --(BUSINESS WIRE)--Dec. 21, 2017-- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that vTv Therapeutics LLC has entered into a global licensing agreement with Reneo Pharmaceuticals , a privately-held biotechnology company focused on developing treatments for orphan diseases.
View HTML
Toggle Summary vTv Therapeutics Announces Licensing Agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co. to Rights for vTv’s GLP-1r Agonist Diabetes Program in China and Other Pacific Rim Territories
HIGH POINT, N.C. --(BUSINESS WIRE)--Dec. 21, 2017-- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that vTv Therapeutics LLC has entered into a licensing agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (“Huadong Pharmaceutical”) , a wholly-owned subsidiary of Huadong Medicine
View HTML
Toggle Summary vTv to Host Key Opinion Leader Event to Discuss the Current State of Clinical Development in Alzheimer’s Disease
HIGH POINT, N.C. --(BUSINESS WIRE)--Nov. 13, 2017-- vTv Therapeutics Inc.  (Nasdaq:VTVT) today announced that the Company will host a key opinion leader (KOL) presentation and webcast focused on the current state of clinical development in Alzheimer’s disease in New York City on Thursday, November
View HTML
Toggle Summary vTv Therapeutics Initiates Phase 1b/2 Study Evaluating TTP399 for the Treatment of Type 1 Diabetes
As Part of Industry Partnership with JDRF HIGH POINT, N.C. --(BUSINESS WIRE)--Nov. 8, 2017-- vTv Therapeutics Inc.  (Nasdaq: VTVT) announced today the initiation of simplici-T1, an adaptive Phase1b/2 study assessing the pharmacokinetics, pharmacodynamics, safety, and tolerability of TTP399 in adult
View HTML
Toggle Summary vTv Therapeutics Reports Third Quarter 2017 Financial and Operational Results
HIGH POINT, N.C. --(BUSINESS WIRE)--Nov. 1, 2017-- vTv Therapeutics Inc. ( vTv Therapeutics ) (Nasdaq:VTVT) today provided a corporate update and reported financial and operational results for the third quarter ended September 30, 2017 . “We’ve made significant progress in the third quarter of 2017
View HTML
Toggle Summary vTv Therapeutics to Present on Azeliragon at the 10th Clinical Trials on Alzheimer’s Disease (CTAD)
-- Azeliragon is the only receptor for advanced glycation endproducts (RAGE) antagonist in clinical development for Alzheimer’s disease -- HIGH POINT, N.C. --(BUSINESS WIRE)--Oct. 30, 2017-- vTv Therapeutics Inc. (Nasdaq:VTVT), today announced that the Company will present three posters on clinical
View HTML
Toggle Summary vTv Therapeutics Presents Further Dose Response Analysis from Phase 2 Study of its GLP-1 Receptor Agonist at 53rd Annual Meeting of the European Association for the Study of Diabetes
HIGH POINT, N.C. --(BUSINESS WIRE)--Sep. 7, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT) today announced that additional analysis from a Phase 2 clinical study of TTP273, an investigational, oral small molecule GLP-1 receptor (GLP-1R) agonist for the treatment of type 2 diabetes will be
View HTML
Toggle Summary JDRF and vTv Therapeutics Announce Collaboration on Phase 2 Study of Novel Treatment for Type 1 Diabetes
vTv Therapeutics and JDRF enter into a $6 million industry partnership to explore the effect of liver-selective glucokinase activator TTP399 as an insulin-adjunctive therapy in type 1 diabetes HIGH POINT, N.C. --(BUSINESS WIRE)--Sep. 6, 2017-- vTv Therapeutics Inc.
View HTML
Toggle Summary vTv Therapeutics Announces Issuance of U.S. Patent Covering Methods of Treatment Using Azeliragon
HIGH POINT, N.C. --(BUSINESS WIRE)--Aug. 3, 2017-- vTv Therapeutics Inc. (Nasdaq: VTVT) announced today that the U.S. Patent and Trademark Office has issued a patent with claims protecting methods of treatment using azeliragon, the Company’s oral antagonist of the Receptor for Advanced Glycation
View HTML
Toggle Summary vTv Therapeutics Reports Second Quarter 2017 Financial and Operational Results
HIGH POINT, N.C. --(BUSINESS WIRE)--Aug. 2, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT) today provided a corporate update and reported financial and operational results for the second quarter ended June 30, 2017 . “With positive progress in our lead Alzheimer’s and diabetes programs, vTv is
View HTML